Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies

British Journal of Cancer

Volumn 95, Issue 10, 2006, Pages 1342-1347

  Leyvraz, S ^a   Herrmann, R ^b   Guillou, L ^a   Honegger, H P ^c   Christinat, A ^a   Fey, M F ^d   Sessa, C ^e   Wernli, M ^f   Cerny, T ^g   Dietrich, D ^h   Pestalozzi, B ⁱ  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c TRIEMLI HOSPITAL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^f Oncology Hematology Department   (Switzerland)

^g SAKK Coordinating Center ^*  (Switzerland)

^h SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Doxorubicin; Ifosfamide; Salvage surgery; Soft tissue sarcomas

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; HEART FAILURE; HEMATURIA; HISTOLOGY; HUMAN; INFECTION; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SEPTIC SHOCK; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SALVAGE THERAPY; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33751037747     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603420     Document Type: Article

References (36)

1. Antman KH, Ryan L, Elias A, Sherman D, Grier HE (1989) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7: 126-131
2. Benjamin RS (1987) Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma? J Clin Oncol 5: 833-835
3. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF (1999) Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85: 389-395
4. Blay JY, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A, Oosterhuis JW, Judson I, Nielsen OS (2003) Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39: 64-69
5. Bramwell VHC, Anderson D, Charette ML, The Sarcoma Disease Site Group (2003) Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma (review). The Cochrane Database Syst Rev, (3): CD003293, John Wiley and Sons, Ltd
6. Castellanos AM, Fields WS (1986) Grading of neurotoxicity in cancer therapy. J Clin Oncol 4: 1277-1278
7. Cerny T, Leyvraz S, von Briel T, Kupfer A, Schaad R, Schmitz SF, Honegger P, Sessa C, Brunner J, Boddy AV (1999) Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 10: 1087-1094
8. Cosetti M, Wexler LH, Calleja E, Trippett T, LaQuaglia M, Huvos AG, Gerald W, Healey JH, Meyers PA, Gorlick R (2002) Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 24: 101-105
9. De Pas T, De Braud F, Orlando L, Nole F, Munzone E, Zampino MG, Fazio N, Aapro MS, Goldhirsch A (1998) High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol 9: 917-919
10. Dirix LY, Van Oosterom AT (1999) Soft tissue sarcoma in adults. Curr Opin Oncol 11: 285-295
11. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR (1993) Randomized comparison of doxorubicin alone vs ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269-1275
12. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, Schwartz GK, Casper ES (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86: 2034-2037
13. Fayette J, Blay JY (2005) Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004. Curr Opin Oncol 17: 370-375
14. Frustaci S, Buonadonna A, Galligioni E, Favaro D, De Paoli A, Lo RG, Sorio R, Tumolo S, Monfardini S (1997) Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol 15: 1418-1426
15. Grosso F, Demetri GD, Blay JY, Judson I, Le Cesne A, Spreafico C, Jimeno J, Pilotti S, D'Incalci M, Casali PG (2006) Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. J Clin Oncol, ASCO Annual Meeting Proceedings, 9511
16. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15: 350-362
17. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20: 2824-2831
18. Hryniuk W, Goodyear M (1990) The calculation of received dose intensity. J Clin Oncol 8: 1935-1937
19. Judson I (2004) Systemic therapy of soft tissue sarcoma: an improvement in outcome. Ann Oncol 15(Suppl 4): iv193-iv196
20. Küpfer A, Aeschlimann C, Wermuth B, Cerny T (1994) Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 343: 763-764
21. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, Vanel D, Contesso G, Tursz T (1995) High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13: 1600-1608
22. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J (2000) Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide vs highdose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18: 2676-2684
23. Leyvraz S, Bacchi M, Cerny T, Lissoni A, Sessa C, Bressoud A, Hermann R (1998) Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol 9: 877-884
24. Maurel J, Buesa J, Lopez-Pousa A, del Muro XG, Quintana MJ, Martin J, Casado A, Martinez-Trufero J, de Las PR, Balana C (2004a) Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias - a study of the Spanish group for research on sarcomas (GEIS). J Surg Oncol 88: 44-49
25. Maurel J, Fra J, Lopez-Pousa A, Garcia del Muro X, Balana C, Casado A, Martin J, Martinez-Trufero J, de las Penas R, Buesa JM (2004b) Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer 100: 1498-1506
26. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 1-8
27. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655
28. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS (1998) Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21: 317-321
29. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS (1997) High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 15: 2378-2384
30. Reichardt P, Tilgner J, Hohenberger P, Dorken B (1998) Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 16: 1438-1443
31. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, van Glabbeke M, van Oosterom A (1995) Doxorubicin vs CYVADIC vs doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-1545
32. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T (1999) Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracyclinecontaining first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17: 150-157
33. van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, Van Glabbeke M, Verweij J (2002) Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38: 2397-2406
34. -2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 23: 105-112
35. World Health Organization (1979) Handbook for Reporting results for Cancer Treatment, 48, WHO offset publication No 48 (ed). WHO: Geneva
36. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22: 890-899